Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Nyxoah Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Olivier Taelman

İcra Kurulu Başkanı

€807.1k

Toplam tazminat

CEO maaş yüzdesi	54.1%
CEO görev süresi	4.9yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	4.4yrs

Son yönetim güncellemeleri

It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year

Jun 05

Recent updates

It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year

Jun 05

Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt

Jan 24

Do Insiders Own Lots Of Shares In Nyxoah S.A. (EBR:NYXH)?

Dec 21

CEO Tazminat Analizi

Olivier Taelman'un ücretlendirmesi Nyxoah'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-€44m
Mar 31 2024	n/a	n/a	-€43m
Dec 31 2023	€807k	€436k	-€43m
Sep 30 2023	n/a	n/a	-€46m
Jun 30 2023	n/a	n/a	-€44m
Mar 31 2023	n/a	n/a	-€36m
Dec 31 2022	€631k	€436k	-€31m
Sep 30 2022	n/a	n/a	-€24m
Jun 30 2022	n/a	n/a	-€27m
Mar 31 2022	n/a	n/a	-€29m
Dec 31 2021	€731k	€413k	-€28m
Sep 30 2021	n/a	n/a	-€25m
Jun 30 2021	n/a	n/a	-€21m
Mar 31 2021	n/a	n/a	-€16m
Dec 31 2020	€336k	€263k	-€12m

Tazminat ve Piyasa: Olivier 'ın toplam tazminatı ($USD 893.40K ) Belgian pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 759.56K ).

Tazminat ve Kazançlar: Olivier şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Olivier Taelman (53 yo)

4.9yrs

Görev süresi

€807,096

Tazminat

Mr. Olivier Taelman serves as a Vice President of Sales Europe at Autonomic Technologies, Inc. Mr. Olivier Taelman is the Chief Executive Officer at Nyxoah S.A. since November 2019 and serves as its Execu...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Taub	Co-Founder & Chairman	15.3yrs	€127.63k	8.21% € 23.7m
Olivier Taelman	CEO & Executive Director	4.9yrs	€807.10k	Veri yok
Loic Moreau	Chief Financial Officer	2.8yrs	€468.69k	0.038% € 110.8k
Bruno Onkelinx	Chief Technology Officer	3.6yrs	Veri yok	Veri yok
Mikaela Kirkwood	Corporate Communication & Investor Relations Manager	no data	Veri yok	Veri yok
An Moonen	General Counsel	3.8yrs	Veri yok	Veri yok
Inge Vanwittenbergh	Global Human Resource Director	1.8yrs	Veri yok	Veri yok
David DeMartino	Chief Strategy Officer	1.8yrs	Veri yok	Veri yok
Remi Renard	Chief of Staff	less than a year	Veri yok	Veri yok
Jeyakumar Subbaroyan	Chief Clinical Officer	less than a year	Veri yok	Veri yok
Francis Kim	Chief Regulatory & Quality Officer	less than a year	Veri yok	Veri yok
Maurits Boon	Chief Medical Officer	less than a year	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: NYXH 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Taub	Co-Founder & Chairman	15.3yrs	€127.63k	8.21% € 23.7m
Olivier Taelman	CEO & Executive Director	4.1yrs	€807.10k	Veri yok
Kevin Rakin	Independent Non-Executive Director	8.3yrs	€68.59k	0.36% € 1.0m
Jurgen Hambrecht	Independent Non-Executive Director	4.8yrs	€58.50k	3.91% € 11.3m
Daniel Wildman	Independent Non-Executive Director	1.8yrs	€71.28k	Veri yok
Virginia Kirby	Independent Non-Executive Director	2.3yrs	€59.22k	0.016% € 46.6k
Rita Johnson-Mills	Independent Non-Executive Director	3.2yrs	€63.62k	0.016% € 46.6k
Pierre Gianello	Non-Executive Director	6.8yrs	€175.63k	0.034% € 96.9k

4.4yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NYXH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).

Nyxoah Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Nyxoah S.A. Appoints Scott Holstine as Chief Commercial Officer

It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year

Nyxoah S.A., Annual General Meeting, Jun 12, 2024

Nyxoah S.A. Appoints Christoph Eigenmann as Chief Commercial Officer

Nyxoah S.A. Appoints Daniel Wildman as Independent Director to Its Board of Directors

Nyxoah S.A. Announces Resignation of Raymond Cohen as Member of the Board of Directors

Recent updates

Nyxoah S.A. Presents Dream U.S. Study Data At Isss 2024, Showing Significant Ahi Reduction and Quality-Of-Life Improvements

Consensus revenue estimates decrease by 23%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nyxoah S.A. Appoints Scott Holstine as Chief Commercial Officer

Price target decreased by 7.6% to €13.40

Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA

It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year

New minor risk - Shareholder dilution

Nyxoah S.A. has filed a Follow-on Equity Offering.

First quarter 2024 earnings released: €0.41 loss per share (vs €0.46 loss in 1Q 2023)

Full year 2023 earnings released: €1.51 loss per share (vs €1.21 loss in FY 2022)

New major risk - Revenue and earnings growth

Nyxoah S.A., Annual General Meeting, Jun 12, 2024

Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt

New major risk - Share price stability

Price target decreased by 13% to €9.65

Nyxoah SA Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio(R)

Consensus revenue estimates decrease by 16%, EPS upgraded

New major risk - Revenue and earnings growth

New major risk - Financial position

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 14%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings released: €0.45 loss per share (vs €0.19 loss in 2Q 2022)

First quarter 2023 earnings released: €0.46 loss per share (vs €0.26 loss in 1Q 2022)

Nyxoah S.A. Appoints Christoph Eigenmann as Chief Commercial Officer

Full year 2022 earnings released: €1.21 loss per share (vs €1.16 loss in FY 2021)

Nyxoah S.A. to Report Q3, 2023 Results on Nov 08, 2023

Nyxoah S.A. Appoints Daniel Wildman as Independent Director to Its Board of Directors

Third quarter 2022 earnings released: €0.24 loss per share (vs €0.29 loss in 3Q 2021)

Nyxoah S.A. Announces Resignation of Raymond Cohen as Member of the Board of Directors

Second quarter 2022 earnings released: €0.19 loss per share (vs €0.31 loss in 2Q 2021)

Nyxoah S.A. Announces CE Mark Approval for Genio® 2.1

Nyxoah SA Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio in Complete Concentric Collapse Patients

Nyxoah S.A. Announces U.S. Food and Drug Administration Approved the Use of Nyxoah's Next Generation Genio 2.1 System

Nyxoah S.A. Announces Board Changes

Nyxoah S.A. to Report First Half, 2022 Results on Aug 09, 2022

Nyxoah S.A. to Report Fiscal Year 2021 Results on Mar 24, 2022

Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse

Nyxoah Deleted from Other OTC

Nyxoah SA's BETTER SLEEP Trial Reaches its Primary Endpoints

New 90-day high: €19.90

Nyxoah Receives FDA Approval for Full-Body 1.5T and 3T MRI Compatibility for the Genio System to Treat Obstructive Sleep Apnea

New 90-day high: €18.50

Nyxoah S.A. Announces First US Patient Implanted in the DREAM Pivotal IDE Study, with the Genio System for the Treatment of Obstructive Sleep Apnea

Do Insiders Own Lots Of Shares In Nyxoah S.A. (EBR:NYXH)?

Nyxoah S.A. Announces First Patient Implanted in the Dream US Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea

Nyxoah S.A. has filed an IPO in the amount of €75.67805 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş